TQB-2619

N/A

Report date: 2025/01/26 17:07:30

Base Information

Drug NameTQB-2619
Drug Alias NameTQB-2619
ClassificationBiologics
Mechanisms of ActionC-C chemokine receptor type 4 antagonists
TargetsC-C chemokine receptor type 4
Therapy Area/IndicationsLymphoma, T-CellLeukemia, Lymphoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLeukemia, Lymphoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A